JP4452914B2 - 新規トランスポータタンパク質 - Google Patents
新規トランスポータタンパク質 Download PDFInfo
- Publication number
- JP4452914B2 JP4452914B2 JP2003315306A JP2003315306A JP4452914B2 JP 4452914 B2 JP4452914 B2 JP 4452914B2 JP 2003315306 A JP2003315306 A JP 2003315306A JP 2003315306 A JP2003315306 A JP 2003315306A JP 4452914 B2 JP4452914 B2 JP 4452914B2
- Authority
- JP
- Japan
- Prior art keywords
- hydantoin
- amino acid
- protein
- transporter
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010078791 Carrier Proteins Proteins 0.000 title description 112
- 229940091173 hydantoin Drugs 0.000 claims description 172
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims description 109
- 108090000623 proteins and genes Proteins 0.000 claims description 98
- 108020004414 DNA Proteins 0.000 claims description 83
- -1 hydantoin compound Chemical class 0.000 claims description 79
- 102000004169 proteins and genes Human genes 0.000 claims description 75
- 241000588724 Escherichia coli Species 0.000 claims description 41
- 102000040811 transporter activity Human genes 0.000 claims description 39
- 108091092194 transporter activity Proteins 0.000 claims description 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 37
- 150000001469 hydantoins Chemical class 0.000 claims description 26
- 230000032258 transport Effects 0.000 claims description 22
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 21
- 239000013612 plasmid Substances 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 108020004511 Recombinant DNA Proteins 0.000 claims description 15
- 241001468202 Microbacterium liquefaciens Species 0.000 claims description 14
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 14
- 238000003780 insertion Methods 0.000 claims description 11
- 230000037431 insertion Effects 0.000 claims description 11
- 125000000539 amino acid group Chemical group 0.000 claims description 10
- 238000012217 deletion Methods 0.000 claims description 10
- 230000037430 deletion Effects 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 244000005700 microbiome Species 0.000 claims description 8
- 229960000458 allantoin Drugs 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- DBOMTIHROGSFTI-UHFFFAOYSA-N 5-benzylimidazolidine-2,4-dione Chemical compound O=C1NC(=O)NC1CC1=CC=CC=C1 DBOMTIHROGSFTI-UHFFFAOYSA-N 0.000 claims description 6
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 5
- KAVIACMZMOXBMP-UHFFFAOYSA-N 5-(indol-1-ylmethyl)imidazolidine-2,4-dione Chemical compound O=C1NC(=O)NC1CN1C2=CC=CC=C2C=C1 KAVIACMZMOXBMP-UHFFFAOYSA-N 0.000 claims description 4
- 241001467578 Microbacterium Species 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000006301 indolyl methyl group Chemical group 0.000 claims description 4
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims description 4
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000005358 mercaptoalkyl group Chemical group 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 89
- 239000000758 substrate Substances 0.000 description 66
- 235000018102 proteins Nutrition 0.000 description 58
- 238000000034 method Methods 0.000 description 48
- 102000004190 Enzymes Human genes 0.000 description 37
- 108090000790 Enzymes Proteins 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 35
- 239000012528 membrane Substances 0.000 description 35
- 150000001413 amino acids Chemical class 0.000 description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 238000007792 addition Methods 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 108010088443 hydantoin racemase Proteins 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 108090000604 Hydrolases Proteins 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 230000000813 microbial effect Effects 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- 102100036238 Dihydropyrimidinase Human genes 0.000 description 6
- 108091022884 dihydropyrimidinase Proteins 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000002983 circular dichroism Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000007928 solubilization Effects 0.000 description 5
- 238000005063 solubilization Methods 0.000 description 5
- 241000589159 Agrobacterium sp. Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 102000004157 Hydrolases Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 241000606583 Rodentibacter pneumotropicus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000005273 aeration Methods 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 230000006957 competitive inhibition Effects 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 238000001142 circular dichroism spectrum Methods 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 241000589564 Flavobacterium sp. Species 0.000 description 2
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 241000157908 Paenarthrobacter aurescens Species 0.000 description 2
- 241000589774 Pseudomonas sp. Species 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 230000009056 active transport Effects 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 229960003669 carbenicillin Drugs 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- JMOHQJVXBQAVNW-UHFFFAOYSA-M sodium;2,4-dinitrophenolate Chemical compound [Na+].[O-]C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O JMOHQJVXBQAVNW-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 241000588630 Moraxella nonliquefaciens Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 101710137382 Protein ORF5 Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000008955 bacterial trafficking Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000010359 gene isolation Methods 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 101150019416 trpA gene Proteins 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003315306A JP4452914B2 (ja) | 2003-09-08 | 2003-09-08 | 新規トランスポータタンパク質 |
| EP04787749A EP1666588B1 (en) | 2003-09-08 | 2004-09-08 | Novel transporter protein |
| PCT/JP2004/013066 WO2005038021A1 (ja) | 2003-09-08 | 2004-09-08 | 新規トランスポータタンパク質 |
| US11/276,614 US7320794B2 (en) | 2003-09-08 | 2006-03-08 | Transporter protein |
| US11/946,113 US7851610B2 (en) | 2003-09-08 | 2007-11-28 | Transporter protein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003315306A JP4452914B2 (ja) | 2003-09-08 | 2003-09-08 | 新規トランスポータタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005080553A JP2005080553A (ja) | 2005-03-31 |
| JP2005080553A5 JP2005080553A5 (enExample) | 2006-10-12 |
| JP4452914B2 true JP4452914B2 (ja) | 2010-04-21 |
Family
ID=34415622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003315306A Expired - Fee Related JP4452914B2 (ja) | 2003-09-08 | 2003-09-08 | 新規トランスポータタンパク質 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US7320794B2 (enExample) |
| EP (1) | EP1666588B1 (enExample) |
| JP (1) | JP4452914B2 (enExample) |
| WO (1) | WO2005038021A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4806963B2 (ja) * | 2005-05-20 | 2011-11-02 | 味の素株式会社 | β−ヒドロキシアミノ酸の製造方法およびこれに用いる酵素 |
| JP4877227B2 (ja) * | 2005-05-20 | 2012-02-15 | 味の素株式会社 | Ｌ−セリン誘導体の製造方法およびこれに用いる酵素 |
| WO2009091045A1 (ja) * | 2008-01-18 | 2009-07-23 | Ajinomoto Co., Inc. | セリン誘導体の製造方法及びこれに用いるタンパク質 |
| JPWO2009139392A1 (ja) * | 2008-05-12 | 2011-09-22 | 味の素株式会社 | β−アラニルアミノ酸またはその誘導体の製造方法 |
| WO2016183532A1 (en) * | 2015-05-13 | 2016-11-17 | Synlogic, Inc. | Bacteria engineered to treat a disease or disorder |
| US9688967B2 (en) | 2014-12-05 | 2017-06-27 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| AR102981A1 (es) | 2014-12-11 | 2017-04-05 | Harvard College | Inhibidores de la necrosis celular y métodos de preparación de los mismos |
| US11883439B2 (en) | 2015-05-13 | 2024-01-30 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
| CA2985819A1 (en) | 2015-05-13 | 2016-11-17 | Synlogic, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| US11618894B2 (en) | 2015-11-16 | 2023-04-04 | Synlogic Operating Company, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| CN111655841A (zh) | 2017-06-21 | 2020-09-11 | 同生运营公司 | 用于治疗紊乱的细菌 |
| JP2023518184A (ja) | 2020-03-20 | 2023-04-28 | シンロジック オペレーティング カンパニー インコーポレイテッド | 高フェニルアラニン血症を軽減するように遺伝子改変された微生物 |
| WO2025113599A1 (zh) * | 2023-11-30 | 2025-06-05 | 长春金赛药业有限责任公司 | 抗gh单域抗体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999051722A2 (de) * | 1998-04-02 | 1999-10-14 | Degussa-Hüls Aktiengesellschaft | Rekombinante l-n-carbamoylase aus arthrobacter aurescens, verfahren zur herstellung von l-aminosäuren mittels dieser |
| US6713288B1 (en) * | 1999-09-28 | 2004-03-30 | University Of Stuttgart | Whole cell catalysts |
| JP3814126B2 (ja) | 2000-06-30 | 2006-08-23 | ジヤトコ株式会社 | 自動変速機の入力クラッチ潤滑制御装置 |
| EP1188826B1 (en) * | 2000-09-13 | 2011-06-08 | Ajinomoto Co., Inc. | 5-substituted hydantoin racemase, DNA coding for the same, and process for producing optically active amino acids |
| JP4529338B2 (ja) * | 2001-03-08 | 2010-08-25 | 味の素株式会社 | ヒダントイナーゼをコードするｄｎａ、ｎ−カルバミル−ｌ−アミノ酸ハイドロラーゼをコードするｄｎａ、組み換えｄｎａ、形質転換された細胞、タンパク質の製造方法および光学活性アミノ酸の製造方法 |
| JP4485734B2 (ja) * | 2002-01-22 | 2010-06-23 | 味の素株式会社 | ５置換ヒダントインラセマーゼ、これをコードするｄｎａ、組み換えｄｎａ、形質転換された細胞および光学活性アミノ酸の製造方法 |
| EP1743943A4 (en) * | 2004-03-17 | 2012-01-18 | Ajinomoto Kk | PROCESS FOR PREPARING L-FUCULOSE AND METHOD FOR PRODUCING L-FUCOSE |
| JP4806963B2 (ja) * | 2005-05-20 | 2011-11-02 | 味の素株式会社 | β−ヒドロキシアミノ酸の製造方法およびこれに用いる酵素 |
-
2003
- 2003-09-08 JP JP2003315306A patent/JP4452914B2/ja not_active Expired - Fee Related
-
2004
- 2004-09-08 WO PCT/JP2004/013066 patent/WO2005038021A1/ja not_active Ceased
- 2004-09-08 EP EP04787749A patent/EP1666588B1/en not_active Expired - Lifetime
-
2006
- 2006-03-08 US US11/276,614 patent/US7320794B2/en not_active Expired - Fee Related
-
2007
- 2007-11-28 US US11/946,113 patent/US7851610B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1666588B1 (en) | 2011-05-11 |
| US20060183190A1 (en) | 2006-08-17 |
| WO2005038021A1 (ja) | 2005-04-28 |
| EP1666588A4 (en) | 2008-04-23 |
| US7851610B2 (en) | 2010-12-14 |
| EP1666588A1 (en) | 2006-06-07 |
| US7320794B2 (en) | 2008-01-22 |
| JP2005080553A (ja) | 2005-03-31 |
| US20090253168A1 (en) | 2009-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7851610B2 (en) | Transporter protein | |
| JPH04228079A (ja) | セファロスポリン・アセチルハイドロラーゼ遺伝子および該遺伝子にコードされるタンパク質 | |
| WO1998048030A1 (en) | Process for producing optically active amino compounds | |
| JP3915983B2 (ja) | プロテアーゼ、このプロテアーゼをコードするｄｎａ、プロテアーゼの製造方法 | |
| JP2971218B2 (ja) | ウリカーゼ遺伝子およびウリカーゼの製造法 | |
| US20130302853A1 (en) | Compositions and methods of producing enterokinase in yeast | |
| JP2000509980A (ja) | アミンアシラーゼ活性を有するバイオ触媒 | |
| JP4880859B2 (ja) | 新規カルボニル還元酵素、その遺伝子、およびその利用法 | |
| Nagayoshi et al. | Purification and characterization of human brain serine racemase expressed in moderately halophilic bacteria | |
| JP2010187658A (ja) | Ｄ−フェニルセリンデアミナーゼ及びその利用 | |
| CA2365594A1 (en) | Microbiological production method for .alpha.-l-aspartyl-l-phenylalanine | |
| US5985632A (en) | Peptide amidase from xanthomonas | |
| JPWO2002010399A1 (ja) | 新規カルボニル還元酵素、その遺伝子、およびその利用法 | |
| US6214590B1 (en) | 2-aminothiazoline-4-carboxylate racemase and gene encoding therefor | |
| WO2000008170A1 (en) | Gene participating in the production of homo-glutamic acid and utilization thereof | |
| CN101068925B (zh) | 含有与l-肉碱生物合成相关基因的肠杆菌科属微生物和使用该微生物生产l-肉碱的方法 | |
| JP4251446B2 (ja) | アルデヒド脱水素酵素をコードする遺伝子 | |
| JP3477746B2 (ja) | 魚由来トランスグルタミナーゼ遺伝子 | |
| JP4116798B2 (ja) | 新規アミダーゼ及びそれをコードする遺伝子 | |
| JP3330670B2 (ja) | アルケンモノオキシゲナーゼ、これをコードする遺伝子及び形質転換微生物並びにアルケンのエポキシ化方法 | |
| JPH0556787A (ja) | エステル不斉加水分解酵素遺伝子 | |
| JP2004105152A (ja) | （ｒ）−体のアミド結合を選択的に加水分解するアミダーゼ遺伝子及びその利用 | |
| WO2005035750A2 (en) | Transgenic organisms with lower growth temperature | |
| BRPI0609675A2 (pt) | método para produzir uma proteìna | |
| JPH07184660A (ja) | 超耐熱性プロテアソーム |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060824 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060824 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090929 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091124 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100105 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100118 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130212 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130212 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130212 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |